Helios, an Ikaros family transcription factor, is preferentially expressed at the mRNA and protein level in regulatory T cells. Helios expression previously appeared to be restricted to thymic-derived Treg. Consistent with recent data, we show here that Helios expression is inducible in vitro under certain conditions. To understand phenotypic and functional differences between Helios + and Helios 2 Treg, we profiled cell-surface markers of FoxP3 + Treg using unmanipulated splenocytes. We found that CD103 and GITR are expressed at high levels on a subset of Helios + Treg and that a Helios + Treg population could be significantly enriched by FACS sorting using these two markers. Quantitative real-time PCR (qPCR) analysis revealed increased TGF-b message in Helios + Treg, consistent with the possibility that this population possesses enhanced regulatory potential. In tumor-bearing mice, we found that Helios + Treg were relatively over-represented in the tumor-mass, and BrdU studies showed that, in vivo, Helios + Treg proliferated more than Helios 2 Treg. We hypothesized that Heliosenriched Treg might exert increased suppressive effects. Using in vitro suppression assays, we show that Treg function correlates with the absolute number of Helios + cells in culture. Taken together, these data show that Helios + Treg represent a functional subset with associated CD103 and GITR expression.
Introduction
Regulatory T cells (Treg) are a CD4 subset that suppresses the function of multiple types of hematopoetic effector cells. This functionality most likely evolved to prevent the development of autoimmunity as a consequence of over-exuberant immune activation [1] [2] [3] [4] [5] . Correspondingly, Treg down-regulate immunity to certain pathogens [6] , a property that appears to have been hijacked by tumors [5] [6] [7] in their efforts to escape immune surveillance. In general, Treg are characterized by the expression of the FoxP3 transcription factor [8] , although some studies indicate that functional Treg can develop in the absence of Foxp3 [9] . One broad classification of Treg is based on the notion that some FoxP3 positive cells appear to be thymic-derived (natural Treg or nTreg), while other FoxP3 positive cells are induced peripherally (induced Treg or iTreg) [10] .
Several microarray studies [11] [12] [13] , including our own [14] , showed a relative upregulation of the Ikaros family transcription factor Helios in Treg. In addition, two recent studies suggested that Helios expression might distinguish thymic-derived from induced Treg [15, 16] . However, this notion was recently challenged by a clear demonstration of Helios expression induced in transgenic CD4 T cells upon recognition of their cognate antigen in the presence of IL-2 and TGF-b [17] . These data suggest that the method of activation could determine Helios expression in iTreg, a finding so far unexplored in a non-TCR transgenic CD4
+ T cell population. A functional role for Helios in either natural or induced Treg remains unclear. Previous studies by our group have demonstrated that Helios binds to the FoxP3 promoter and upregulates FoxP3 expression [16] . Homozygous deletion of Helios was neonatally lethal in C57/Bl6 mice; the etiology for that early death remains unexplained. However, on a mixed background (129/Sv:B6), knocking out Helios did not appear to affect the absolute number of Treg or interfere with their function [18] . Using a targeted approach, Thorton et al. deleted Helios in CD4 cells by crossing CD4-Cre mice to Helios-fl/fl animals [15] . Consistent with the results from the genomic knockout studies, no defect in Heliosdeficient Treg function was noted. Forced over-expression of Helios in Treg has not been well-described; indeed, we found that transduction of naïve human CD4 cells with a Helios expression construct appeared to induce apoptosis [16] . Based on these data, we sought to understand Helios function in Treg using an alternative approach. 
Materials and Methods

Animals
BALB/cJ mice were purchased from The Jackson Laboratory (Bar Harbor, ME). FoxP3-GFP knock-in mice on C57BL/6 background were a generous gift of Dr. S Rudensky (Memorial Sloan Kettering Cancer Center, New York, NY). Mice were studied at 4-8 weeks of age. All animal studies were performed in accordance with protocols approved by the Animal Care and Use Committee of the Johns Hopkins University School of Medicine (animal protocol numbers MO10M44 and M009M100).
In vitro Treg induction
Spleens and axillary lymph nodes were harvested from BALB/ cJ or FoxP3-GFP mice and enriched for CD4
+ cells via magnetic bead separation according to the manufacturer's protocol (Miltenyi Biotec, Auburn, CA). Naïve CD4 T cells (CD4 + CD25 2 CD62L hi ) were obtained by FACS sorting using a FACSAria II (BD, Franklin Lakes, NJ). Cells were skewed toward a Treg phenotype by activation with immobilized aCD3e (clone 145-2c11) (5 mg/mL) and soluble aCD28 (clone 37.51) (1 mg/mL) in the presence of rTGF-b (2.5 ng/mL) and rIL2 (40 ng/mL) in RPMI as previously described or by CD3/CD28 T-activator beads (Invitrogen Dynal, Oslo), in the presence of rTGF-b (2.5 ng/mL) and rIL2 (40 ng/mL) in RPMI [14] . Stimulation by CD3/CD28 microbeads was performed in the absence of APCs.
Flow cytometry and extracellular (ECS) and intracellular staining (ICS)
Fluorescent conjugated monoclonal antibodies were purchased from BD or eBioscience (San Diego, CA) with the exception of aHelios-FITC and aHelios-AF647 which were obtained from Biolegend (San Diego, CA). Gates and quadrants were set based on isotype control staining. MFI values were obtained using FlowJo software (Treestar, Ashland, OR) and are reported as relative MFI values using naïve CD4 T cells (CD4 + CD25
2
FoxP3
2 CD62L hi ) as a comparison.
Treg subset sorting
Spleens and axillary LNs were pooled from BALB/cJ mice and enriched for CD4 + T cells by negative selection using the mouse CD4 + T Cell Isolation Kit II (Miltenyi Biotec). CD4 + CD25 + cells were sorted based upon GITR and CD103 expression using the FACSAria II cell sorter (BD). Intracellular staining for FoxP3 and Helios was performed on the Treg populations obtained after sorting as per the manufacturer's protocol (eBioscience). After sorting, cells were analyzed for sorting purity and FoxP3 and Helios expression using an LSRII (BD) and FACSDiva software (BD).
Quantitative real-time PCR
Total RNA was extracted using the RNeasy Micro Kit (Qiagen, Venlo, Netherlands) and cDNA was synthesized with the SMART PCR cDNA synthesis kit (Clontech, Mountain View, CA). All primers were purchased from Applied Biosystems (Carlsbad, CA); reactions were performed in duplicate in 2 independent experiments using an Applied Biosystems 7500 instrument. Relative mRNA frequencies were calculated in relation to 16 s mRNA expression as follows: 2 DD C t where DDC t = (DC t calibration 2DC t sample ).
In vitro suppression assay
These assays were performed as previously described [19] . Briefly, spleens and axillary lymph nodes from BALB/cJ mice were pooled and enriched for CD4 + T cells by negative selection (Miltenyi Biotec On days 8 and 9 post tumor injection, animals were injected IP with 2 mg of BrdU solution (BD). 24 hours after the second BrdU injection, mice were sacrificed and their spleens, axillary lymph nodes, tumor draining inguinal lymph nodes, and tumor infiltrating lymphocytes were isolated and stained for flow cytometric analysis. Extracellular staining was performed as previously described and cells were then incubated in Fix-Perm buffer (eBiosciences) for 16 hours. Cells were washed in Perm Buffer (eBiosciences) and were then DNAse (BD) treated for 1 hour at 37uC, washed in Perm Buffer and stained intracellularly for FoxP3, Helios, and BrdU.
Statistical Analysis
Statistical analysis was performed using Prism 5 (GraphPad, La Jolla, CA). Unpaired two-tailed t-tests were conducted and considered significant at p-values#0.05 (*), 0.01 (**) and 0.001 (***).
Results
Helios upregulation in in vitro induced Treg
Based on recent data [17] , we hypothesized that Helios expression could be induced in Treg derived from a naïve, bulk CD4 population in vitro. To test this hypothesis, naïve CD4 T cells were obtained from wildtype mice using CD62L as a marker for the naïve population. As shown in Figure 1A , less than 1% of these naïve T cells were positive for both FoxP3 and Helios. After 48 hours of stimulation in the presence of TGF-b and IL-2, approximately 87% of the CD4 cells expressed FoxP3. A FoxP3
+
Helios
+ population was clearly observed, representing 33% of total cells. Identical results were obtained using CD45RB as a marker for naïve cells (data not shown). We extended these results using FoxP3-GFP reporter mice [11] (Figure 1B ), here sorting for naïve (CD62L hi ) GFP 2 cells. These data confirmed the observation that Helios expression indeed depends on the TCR signal provided: immobilized aCD3/soluble aCD28 induced significant FoxP3, but did not induce appreciable Helios, consistent with previous studies [15, 16] . Significantly, increasing either immobilized aCD3 or soluble aCD28 signaling was not sufficient to induce appreciable Helios expression ( Figure S1 ). However, when TCR signaling was provided with aCD3/aCD28 microbeads in the absence of APCs, a significant percentage of cultured cells once again co-expressed both FoxP3 and Helios. Taken together these data are support a model in which Helios expression is not exclusive to natural Treg, and show that Helios expression can be induced in vitro under certain stimulation conditions.
Relative over-expression of GITR and CD103 on splenic Helios+ Treg (Figure 2A ). We also determined the relative cell surface phenotype of in vitro induced Helios + versus Helios 2 Treg ( Figure 2D ). As expected, all four populations of Treg showed a relative increase in CD25 expression as compared to FoxP3 2 CD4 T cells (show in in green in Figure 2B and Figure 2D ). There was no significant difference in the expression of either CCR7 or CD127 between Helios + and Figure 1 . Helios up-regulation in induced Treg is determined by TCR signal. A) Wildtype mice: Naïve CD4 + T cells were purfied by sorting, and stimulated in vitro in the presence of TGF-b and aCD3/aCD28 microbeads. 48 hours post stimulation, Helios and FoxP3 expression was assayed by intracellular staining. Data shown are representative of 2 independent experiments, n = 5. B) FoxP3-GFP mice: Naïve, GFP 2 cells were obtained by sorting and stimulated in vitro with either monoclonal antibodies or aCD3/aCD28 beads. As above, Helios and FoxP3 expression was assayed after 48 hours. Data shown are representative of 2 independent experiments, n = 5. doi:10.1371/journal.pone.0034547.g001
2 Treg. Direct ex vivo, Helios + Treg expressed LFA-1 to a significantly greater extent than Helios 2 Treg; but the in vitro induced Treg showed the opposite expression pattern. Interestingly, a subset of the direct ex vivo Helios + Treg exhibited a significantly higher level of expression of both GITR and CD103 as compared to their Helios 2 counterparts. This trend was also observed for the in vitro induced Treg, but was not as pronounced. We further examined these differences in expression levels by comparing the relative MFI for each population, using the MFI of FoxP3 2 CD4 T cells as a control ( Figure 2C and 2E), finding that the MFI of GITR and CD103 was increased on Helios + as opposed to Helios 2 Treg. Taken together, these data suggest that sorting ex vivo CD4 + T cells on GITR and CD103 (in addition to CD4 and CD25) could potentially enrich a Helios + FoxP3 + Treg population for further study. It should be noted that the relative over-expression GITR and CD103 on Helios+ versus Helios-Treg was also observed on the induced Treg as well, but those differences were small in magnitude; thus we focused our future studies on the direct ex vivo Treg populations.
Helios is relatively enriched in a sorted CD103
+ GITR
+
Treg population
We used this difference in the expression of GITR and CD103 to enrich for Helios + Treg by FACS sorting using only extracellular markers. The sorting strategy, shown in Figure 3A, 
CD25
+ population. Interestingly, sorting CD4 + CD25 + cells on GITR alone provided a modest enrichment for Helios expression compared to sorting on CD4 and CD25, but not as much as by sorting on both GITR and CD103. We next explored differences in the expression of several Treg associated transcripts, at the mRNA level, in the populations obtained through sorting, comparing mRNA expression levels in the post-sort Treg populations using qPCR. For these studies, relative mRNA expression was compared to that in naïve CD4 + T cells ( Figure 3B ). The increased level of expression of Helios seen at the protein level in the CD103
+ GITR + population compared to the CD103 2 GITR low population was also observed at the mRNA level: Helios mRNA expression was tenfold higher in Helios
Treg. We found a decreased expression of FoxP3 mRNA in the CD103 2 GITR low population, which supports the finding that the CD4 + CD25 + CD103 2 GITR low population shows slightly decreased levels of FoxP3 protein expression by FACS analysis ( Figure 3A) . Interestingly, the Helios + enriched CD103 + GITR + population showed relatively increased expression of LAG-3, which has been suggested to be a marker of functional Treg [20, 21] 
Proliferating Helios + Treg are a major population in tumors
Given the well-documented role of Treg in attenuating an antitumor immune response [5, 7] , we next examined the number and relative proliferation of Helios + versus Helios 2 Treg in tumorbearing mice. To perform these studies, wildtype BALB/c mice were inoculated with 4T1 mammary tumors, and harvested 10 days after implantation. Interestingly, CD4 + FoxP3 + Helios + Treg appeared to be relatively enriched in the tumor parenchyma as compared to corresponding spleens ( Figure 4A ). Quantitative analyses verified these observations by supporting the concept that Helios + Treg are significantly more prevalent in the tumor parenchyma than are Helios 2 Treg ( Figure 4B ). In non-tumor bearing mice, the ratio of Helios + to Helios 2 Treg in the spleen and axillary lymph nodes was approximately the same as in tumorbearing mice (data not shown). More significantly, the Helios + Treg in the tumor showed a greater extent of BrdU incorporation than Helios 2 Treg in the same site ( Figure 4C ). This observation was not limited to the spleen; in all tissues examined Helios + Treg showed greater BrdU incorporation than their Helios 2 counterparts ( Figure 4D ). Interestingly, we further found that in Treg from tumors CD103 no longer distinguished between Helios 2 and Helios + Treg (data not shown), a finding consistent with recently published data [22] , but which compromised our ability to perform functional analyses of Helios + versus Helios 2 Treg derived from the tumor-infiltrating population. In total, these data show that the predominant FoxP3 + population found within tumor parenchyma expresses Helios and proliferates more robustly in comparison to their Helios 2 counterparts.
Correlation of in vitro Treg suppressive function with Helios expression
Based on the finding that TGF-b is relatively over-expressed at the message level in Helios enriched (CD103 + GITR + ) Treg, we hypothesized that these Helios-enriched Treg might demonstrate a (Figure 5A-B) . As expected, at most of the suppressor to effector ratios examined, the CD4 +
CD25
+ bulk Treg population showed a titratable suppression phenotype. However, the Helios/FoxP3 enriched CD4
Treg population demonstrated significantly increased suppressive capabilities at most ratios examined. Furthermore, the CD4
+ Tregs still showed moderate suppressive function even at a 1:25 ratio ( Figure 5A ). In order to further examine the differences in the suppressive capabilities of these subpopulations, we assayed the three populations shown in Figure 3A , sorting CD4 +
+ bulk Treg by GITR and CD103. As show in Figure 5C Figure 5F ). Taken together, these data show that several suppressor populations exist within the bulk CD4 +
+ Treg population, and that enriching for FoxP3
+
Helios
+ Tregs results in an increased in vitro suppressive capability.
Discussion
Microarray data from several groups [11] [12] [13] , including our own [14] , showed increased expression of the Ikaros family transcription factor Helios in regulatory T cells (Treg). Recently, Thorton et al. [15] utilized a new monoclonal antibody to confirm these observations at the protein level. This group further suggested that Helios expression might serve to distinguish natural (thymic-derived) from peripherally derived Treg, a finding consistent with our data as well [16] . However, the notion that Helios could distinguish between those two populations was subsequently challenged by data showing Helios expression in TCR transgenic cells induced toward a Treg phenotype in vitro.
Here we extend those more recent data, showing that in vitro stimulation of naïve CD4 T cells in the presence of IL-2 and TGFb can lead to the development of both Helios + and Helios 
FoxP3
+ Treg. The function, if any, of Helios in Treg remains relatively unknown. Indeed, either global Helios knockout [18] or CD4-targeted Helios knockout [15] mice showed no overt deficiency in Treg number or function. Our efforts to over-express Helios in naïve CD4 cells have been, to date, thwarted by the observation that successful expression seems to induce apoptosis [16] . We thus set out to study the Helios + population of Treg by elucidating a set of cell surface markers that could enrich CD4 + CD25 + cells for a Helios-expressing population. Interestingly, we found that expression of the glucocorticoid-induced TNF receptor (GITR), a well-accepted Treg molecule [23] , correlated with Helios expression in unstimulated splenic Treg. These data represented our first data suggesting that Helios + Treg might represent an activated, functional population. CD103, an a/b integrin associated with gut-homing of lymphocytes [24] , and preferentially expressed on tumor-infiltrating Treg [22] was also relatively up-regulated on Helios + versus Helios 2 Treg, again suggesting the potential for an increased functional capacity [25, 26] . These data are consistent with a recent large-scale microarray analysis of Treg subtypes, which also showed that Helios message correlates with CD103 expression [27] .
By sorting unstimulated Treg from the spleens of unmanipulated wild-type mice on CD4, CD25, GITR and CD103, we were able to isolate a FoxP3 + Treg population relatively enriched for Helios expression. Our results must be tempered by the notion that this was a relative (2 to 3) fold over-expression as compared to GITR low CD103 [25, 28, 23] , and our data suggests that this difference may correlate with Helios expression. Interestingly, the degree of suppression in any of our Treg assays was closely proportional to the absolute number of Helios + cells admixed, providing reasonable support for the notion that Helios may be a marker of Treg with functional, suppressive capacity. Our conclusions, however, must be interpreted in the light of recent data, from two separate groups, showing that Helios knockout did not affect Treg number or function [15] [16] [17] [18] . One interpretation of these findings is that Helios expression in Treg is a non-essential correlate of CD103 and GITR expression, and is thus not at all necessary for Treg activity in vivo. Another possibility is that multiple Ikaros family members operate in concert to modulate Treg function, as has been observed for Ikaros and Helios in determining SHIP expression in B cells [29] . Despite these caveats, our data support the notion that Helios expression, while likely not absolutely required for Treg function, correlates with the functional capacity of Treg in vitro. Supporting Information Figure S1 Increasing concentrations of a-CD3 and/or a-CD28 do not result in significant Helios induction in vitro. A) Experiments were performed in the same fashion as in Figure 1B .Cells were stimulated with either 0, 5, 10, or 25 mg/mL of plate bound a-CD3 and 1.25 mg/mL of soluble a-CD28. B) Cells were stimulated with either 0, 5, 10, or 25 mg/mL of soluble a-CD28 and 1.25 mg/mL of plate bound a-CD3. C) Cells were stimulated with 0, 5, 10, or 25 mg/mL of both plate bound a-CD3 and soluble a-CD28. (TIF)
